Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2013, Article ID 404396, 6 pages
http://dx.doi.org/10.1155/2013/404396
Clinical Study

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer

Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran

Received 23 June 2013; Revised 15 August 2013; Accepted 25 August 2013

Academic Editor: Zsuzsanna Kahán

Copyright © 2013 Hamid Reza Mirzaei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Fossati, C. Confalonieri, V. Torri et al., “Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3439–3460, 1998. View at Google Scholar · View at Scopus
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Effects of chemotherapy and hormoal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, pp. 1687–1717, 2005. View at Google Scholar
  3. R. P. A'Hern, I. E. Smith, and S. R. Ebbs, “Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens,” British Journal of Cancer, vol. 67, no. 4, pp. 801–805, 1993. View at Google Scholar · View at Scopus
  4. E. P. Mamounas, J. Bryant, B. Lembersky et al., “Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3686–3696, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Martin, T. Pienkowski, J. Mackey et al., “Adjuvant docetaxel for node-positive breast cancer,” The New England Journal of Medicine, vol. 352, no. 22, pp. 2302–2313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Roché, P. Fumoleau, M. Spielmann et al., “Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5664–5671, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Bonneterre, V. Dieras, M. Tubiana-Hulin et al., “Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer,” British Journal of Cancer, vol. 91, no. 8, pp. 1466–1471, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. López-Tarruella and M. Martín, “Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer,” Breast Cancer Research, vol. 11, no. 2, article 204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. D. Bear, S. Anderson, A. Brown et al., “The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4165–4174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. I. C. Smith, S. D. Heys, A. W. Hutcheon et al., “Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1456–1466, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. S. D. Heys, T. Sarkar, and A. W. Hutcheon, “Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival,” Breast Cancer Research and Treatment, vol. 90, no. 2, pp. 169–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Martin, T. Pienkowski, J. Mackey et al., “Adjuvant docetaxel for node-positive breast cancer,” The New England Journal of Medicine, vol. 352, no. 22, pp. 2302–2313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Trudeau, F. Charbonneau, K. Gelmon et al., “Selection of adjuvant chemotherapy for treatment of node-positive breast cancer,” The Lancet Oncology, vol. 6, no. 11, pp. 886–898, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Hryniuk and M. N. Levine, “Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer,” Journal of Clinical Oncology, vol. 4, no. 8, pp. 1162–1170, 1986. View at Google Scholar · View at Scopus
  15. W. Hryniuk, “Dosage parameters in chemotherapy of breast cancer,” Breast Disease, vol. 14, pp. 21–30, 2001. View at Google Scholar · View at Scopus
  16. L. Norton and R. Simon, “The Norton-Simon hypothesis revisited,” Cancer Treatment Reports, vol. 70, no. 1, pp. 163–169, 1986. View at Google Scholar · View at Scopus
  17. L. Norton, “A Gompertzian model of human breast cancer growth,” Cancer Research, vol. 48, no. 24 I, pp. 7067–7071, 1988. View at Google Scholar · View at Scopus
  18. M. L. Citron, D. A. Berry, C. Cirrincione et al., “Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741,” Journal of Clinical Oncology, vol. 21, no. 8, pp. 1431–1439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Yeo, T. S. K. Mok, K. K. Tse et al., “Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer,” Anti-Cancer Drugs, vol. 13, no. 6, pp. 655–662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Coukell and D. Faulds, “Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer,” Drugs, vol. 53, no. 3, pp. 453–482, 1997. View at Google Scholar · View at Scopus
  21. V. G. Kaklamani and W. J. Gradishar, “Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?” Clinical Breast Cancer, vol. 4, supplement 1, pp. S26–S33, 2003. View at Google Scholar · View at Scopus
  22. P. Piedbois, D. Serin, F. Priou et al., “Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study,” Annals of Oncology, vol. 18, no. 1, pp. 52–57, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. J. A. Sparano, M. Wang, S. Martino et al., “Weekly paclitaxel in the adjuvant treatment of breast cancer,” The New England Journal of Medicine, vol. 358, no. 16, pp. 1663–1671, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. R. L. Jones, G. Walsh, S. Ashley et al., “A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) versus 3 weekly (standard) for women with early breast cancer,” British Journal of Cancer, vol. 100, no. 2, pp. 305–310, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Nabholtz, C. Falkson, D. Campos et al., “Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial,” Journal of Clinical Oncology, vol. 21, no. 6, pp. 968–975, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. D. J. Sargent, V. Chan, and R. M. Goldberg, “A three-outcome design for phase II clinical trials,” Controlled Clinical Trials, vol. 22, no. 2, pp. 117–125, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Morales, A. Lorenzo, M. Ramos et al., “Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study,” Cancer Chemotherapy and Pharmacology, vol. 53, no. 1, pp. 75–78, 2004. View at Google Scholar · View at Scopus
  28. A. Di Leo, J. Crown, J.-M. Nogaret et al., “A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer,” Annals of Oncology, vol. 11, no. 2, pp. 169–175, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Schwartz, S. M. Domchek, W.-T. Hwang, and K. Fox, “Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer,” Annals of Oncology, vol. 16, no. 2, pp. 247–252, 2005. View at Publisher · View at Google Scholar · View at Scopus